DGAP-News: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Halbjahresbericht Newron veröffentlicht Ergebnisse für das erste Halbjahr 2022 und informiert zu aktuellen F&E- und Geschäftsaktivitäten
President Biden's Executive Order on Promoting Competition in the American Economy, 86 FR 36987 (2021), expressed concerns about the patent system being misused.
The second quarter also saw a number of notable patent transactions, including among NPEs, with some involving assets developed by global technology companies.
On Friday a case was filed in the District of Delaware by Otsuka Pharmaceutical Company LTD against Teva Pharmaceuticals Inc. and their subsidiaries. The